Vismodegib as a Treatment for Multiple Non-locally Advanced Basal Cell Carcinomas

Main Article Content

Robert Frantz
University of Florida

Mitchell Herold
University of Arizona, College of Medicine, Division of Dermatology

Clara Curiel-Lewandrowski
University of Arizona, College of Medicine, Division of Dermatology

Keywords

Basal Cell Carcinoma, Immunotherapy, Cutaneous Oncology

Abstract

We present the case of a 77-year-old female with seven non-locally advanced basal cell carcinomas (BCCs) of the face who achieved a clinical complete response (CR) in six lesions after completing twelve months of Vismodegib monotherapy with tolerable side effects. This case investigates the off-label practical use of Vismodegib monotherapy to treat multiple non-locally advanced BCCs and reduce the surgical burden of disease in select patients.

References

1. Aggarwal P, Knabel P, Fleischer Jr A. United States burden of melanoma and non-melanoma skin cancer from 1990 to 2019. Am Acad Dermatol. 2021 Aug;85(2):388-395.

2. Lanoue J, Goldenberg G. Basal Cell Carcinoma: A Comprehensive Review of Existing and Emerging Nonsurgical Therapies. J Clin Aesthet Dermatol. May 2016;9(5):26-36.

3. Tronconi MC, Solferino A, Giordano L, Borroni R, Mancini L, Santoro A. Tailored Toxicity-Driven Administration of Vismodegib in Patients With Multiple or Locally Advanced Basal Cell Carcinoma: A Pilot Analysis. Front Oncol. 2020;10:563404.

4. Markowitz O, Schwartz M. The Use of Noninvasive Optical Coherence Tomography to Monitor the Treatment Progress of Vismodegib and Imiquimod 5% Cream in a Transplant Patient with Advanced Basal Cell Carcinoma of the Nose. J Clin Aesthet Dermatol. Aug 2016;9(8):37-41.

5. Sofen H, Gross KG, Goldberg LH, et al. A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma. J Am Acad Dermatol. Jul 2015;73(1):99-105.e101.

6 Dummer R, Ascierto PA, Basset-Seguin N, et al. Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion. J Eur Acad Dermatol Venereol. Sep 2020;34(9):1944-1956.

Article Sidebar

PDF KOL SUMMARY
Published
Sep 12, 2022
DOI https://doi.org/10.25251/skin.6.5.13

Article Details

How to Cite
Frantz, R., Herold, M., & Curiel-Lewandrowski, C. (2022). Vismodegib as a Treatment for Multiple Non-locally Advanced Basal Cell Carcinomas. SKIN The Journal of Cutaneous Medicine, 6(5), 421–423. https://doi.org/10.25251/skin.6.5.13
Issue
Vol. 6 No. 5 (2022)
Section
Brief Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.